Key Takeaways
- • Cosette Pharmaceuticals says RYANODEX® (dantrolene sodium) for injectable suspension is fully stocked and available in the U.S. and international markets following its June 2026 acquisition from Eagle Pharmaceuticals.
- • The company reports a successful supply chain transition and says it is leveraging its established manufacturing and distribution capabilities to maintain a dependable supply for healthcare providers.
- • Cosette, a Bridgewater, N.J.-based specialty pharmaceutical company backed by Avista Healthcare Partners and funds managed by Hamilton Lane, frames the acquisition as part of its commitment to expanding access to important medicines.
Summary
Cosette Pharmaceuticals, Inc. announced that RYANODEX® (dantrolene sodium) for injectable suspension is fully stocked and available in the United States and international markets, according to a Business Wire release dated November 10, 2026. Cosette acquired the product from Eagle Pharmaceuticals in June 2026 and reports that it has completed the supply chain transition successfully. The company says it is using its established manufacturing and distribution capabilities to maintain a dependable supply of the treatment for healthcare providers.
Apurva Saraf, President and Chief Executive Officer of Cosette Pharmaceuticals, said the acquisition reflects the company's commitment to expanding access to important medicines and ensuring the supporting infrastructure is in place. He said the successful integration and supply reliability demonstrate the strength of the organization. Brad Leonard, Vice President, Commercial Operations at Cosette, said the company's priority is ensuring hospitals and healthcare providers have dependable access to RYANODEX® so they can focus on delivering timely care.
Cosette describes itself as a U.S.-based specialty pharmaceutical company with corporate headquarters in Bridgewater, New Jersey, and more than 350 team members. The company is backed by Avista Healthcare Partners, a healthcare-focused private equity firm, and by funds managed by Hamilton Lane (Nasdaq: HLNE). The release directs readers to the full Prescribing Information for RYANODEX® for product details. The announcement contains no financial terms of the acquisition or sales figures.
Apurva Saraf, President and Chief Executive Officer of Cosette Pharmaceuticals, said the acquisition reflects the company's commitment to expanding access to important medicines and ensuring the supporting infrastructure is in place. He said the successful integration and supply reliability demonstrate the strength of the organization. Brad Leonard, Vice President, Commercial Operations at Cosette, said the company's priority is ensuring hospitals and healthcare providers have dependable access to RYANODEX® so they can focus on delivering timely care.
Cosette describes itself as a U.S.-based specialty pharmaceutical company with corporate headquarters in Bridgewater, New Jersey, and more than 350 team members. The company is backed by Avista Healthcare Partners, a healthcare-focused private equity firm, and by funds managed by Hamilton Lane (Nasdaq: HLNE). The release directs readers to the full Prescribing Information for RYANODEX® for product details. The announcement contains no financial terms of the acquisition or sales figures.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.